Proportion and clinical features of never-smokers with non-small cell lung cancer  

作　　者：Jaeyoung Cho Sun Mi Choi Jinwoo Lee Chang-Hoon Lee Sang-Min Lee Dong-Wan Kim Jae-Joon Yim Young Tae Kim Chul-Gyu Yoo Young Whan Kim Sung Koo Han Young Sik Park 

机构地区：[1]Department of Internal Medicine,Seoul National University Hospital,Seoul 110-744,Republic of Korea [2]Department of Thoracic and Cardiovascular Surgery,Seoul National University Hospital,Seoul 110-744,Republic of Korea

出　　处：《Chinese Journal of Cancer》2017年第2期81-87,共7页

摘　　要：Background: The proportion of never?smokers with non?small cell lung cancer(NSCLC) is increasing, but that in Korea has not been well addressed in a large population. We aimed to evaluate the proportion and clinical features of never?smokers with NSCLC in a large single institution.Methods: We analyzed clinical data of 1860 consecutive patients who were newly diagnosed with NSCLC between June 2011 and December 2014.Results: Of the 1860 NSCLC patients, 707(38.0%) were never?smokers. The proportions of women(83.7% vs. 5.6%) and adenocarcinoma(89.8% vs. 44.9%) were higher among never?smokers than among ever?smokers. Significantly more never?smokers were diagnosed at a younger median age(65 vs. 68 years, P < 0.001) and earlier stage(stage I–II, 44.5% vs. 38.9%, P < 0.001) a= 0.015) compared with ever?smokers. Epidermal growth factor receptor mutations(57.8% vs. 24.4%, Pnd anaplastic lymphoma kinase rearrangements(7.8% vs. 2.8%, P < 0.001) were more common in never?smokers, whereas Kirsten rat sarcoma viral oncogene homolog mutations(5.8% vs. 9.6%, P ntly encountered in never?smokers than in ever?smokers. Never?smokers showed longer su= 0.021) were less frequervival after adjust?ing for the favorable effects of younger age, female sex, adenocarcinoma histology, better performance status, early stage disease, being asymptomatic at diagnosis, received antitumor treatment, and the presence of driver mutations(hazard ratio, 0.624; 95% confidence interval, 0.460–0.848; P = 0.003).Conclusions: More than one?third of the Korean patients with NSCLC were never?smokers. NSCLC in never?smokers had different clinical characteristics and major driver mutations and resulted in longer overall survival compared with NSCLC in ever?smokers.Background： The proportion of never-smokers with non-small cell lung cancer （NSCLC） is increasing, but that in Korea has not been well addressed in a large population. We aimed to evaluate the proportion and clinical features of never-smokers with NSCLC in a large single institution.Methods： We analyzed clinical data of 1860 consecutive patients who were newly diagnosed with NSCLC between June 2011 and December 2014.Results： Of the 1860 NSCLC patients, 707 （38.0%） were never-smokers. The proportions of women （83.7% vs. 5.6%） and adenocarcinoma （89.8% vs. 44.9%） were higher among never-smokers than among ever-smokers. Signiicantly more never-smokers were diagnosed at a younger median age （65 vs. 68 years, P 〈 0.001） and earlier stage （stage I–II, 44.5% vs. 38.9%, P = 0.015） compared with ever-smokers. Epidermal growth factor receptor mutations （57.8% vs. 24.4%, P 〈 0.001） and anaplastic lymphoma kinase rearrangements （7.8% vs. 2.8%, P 〈 0.001） were more common in never-smokers, whereas Kirsten rat sarcoma viral oncogene homolog mutations （5.8% vs. 9.6%, P = 0.021） were less frequently encountered in never-smokers than in ever-smokers. Never-smokers showed longer survival after adjust-ing for the favorable efects of younger age, female sex, adenocarcinoma histology, better performance status, early stage disease, being asymptomatic at diagnosis, received antitumor treatment, and the presence of driver mutations （hazard ratio, 0.624; 95% conidence interval, 0.460–0.848; P = 0.003）.Conclusions： More than one-third of the Korean patients with NSCLC were never-smokers. NSCLC in never-smokers had diferent clinical characteristics and major driver mutations and resulted in longer overall survival compared with NSCLC in ever-smokers.

关 键 词：Non-small cell lung carcinoma Never-smoker Epidermal growth factor receptor KRAS PROGNOSIS 

分 类 号：R734.2[医药卫生—肿瘤]